Nonalcoholic Fatty Liver Disease (NAFLD) Pharmacological Treatment: Metformin Versus Atorvastatin

• Status: Unknown status
• Trial end date: 2015-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The first line approach to NAFLD is currently based on diet and lifestyle modification. Aim of our Unit is to compare the efficacy of two different doses of metformin (1 g/day and 2 g/day) with atorvastatin (20 mg/day) on amelioration of inflammatory and cardiometabolic parameters, ultrasound signs and clinical scores associated with liver fibrosis in early-stage NAFLD non-diabetic patients.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Prof Antonino Belfiore
• Treatments: Atorvastatin; Atorvastatin Calcium; Metformin

Criteria

Inclusion Criteria:

• Age <=55

• BMI <=40

• Total cholesterol <=280 mg/dl

• LDL <=180 mg/dl

• Triglycerides <=200 mg/dl

• AST and ALT in the normal range

• Signs of simple liver steatosis at ultrasonorography.

Exclusion criteria:

• Type 2 diabetes

• Heart disease

• Renal failure

• Smoking habit

• Alcohol intake of more than 20 g per day in the case of women and more than 30 g per day in the case of men

• Hepatic virus infection

• Autoimmune, metabolic or genetic liver diseases

• Use of drugs known to induce liver steatosis